• CSPC Pharmaceutical announced Oct. 28, 2026, that its Phase 1 trial of SYS6077 injection for advanced malignant tumors had begun in China.
• The multicenter study received Chinese regulatory clearance in September 2026; participant recruitment and screening are underway.
• SYS6077 is an off-the-shelf mRNA cancer vaccine designed to activate immune responses against multiple tumor neoantigens.
• The trial will assess safety, immune responses and preliminary antitumor activity across different doses.
• Preclinical studies showed tumor-specific T-cell responses and antitumor activity in multiple animal models.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261028-12386085), on October 28, 2026, and is solely responsible for the information contained therein.